Summary:
A Randomized, Multi-regional, Double-blind, Double-dummy Parallel-group Phase 3 study to assess the efficacy and safety of study medication in Gout patients with Hyperuricemia.
Criteria:- Male or Female 18-85 years old
- Have gout with hyperuricemia
- BMI <50 kg
- Not experiencing an active acute gout attack within 2 weeks prior to screening
- No uncontrolled severe pain (e.g. servere osteoarthritis, back pain)
- No cancer in the last 5 years
Qualified Participants May Receive:
Compensation for time and travel.